ATLANTA, Georgia — UCB, a global biopharmaceutical company, today announced that the final analysis of an open-label extension (OLE) study with the objective to describe long-term safety and effectiveness of FINTEPLA (fenfluramine) in Lennox-Gastaut syndrome (LGS) was published in Epilepsy & Behavior.2 No new or unexpected treatment-emergent adverse events (TEAEs) were reported.2 Children and adults...
Latest News
Chicago, Illinois – The University of Chicago Medicine Comer Children’s Hospital will be among the first in the country to offer gene therapy for sickle cell disease in patients 12 years and older, after federal regulators approved two new treatments in December 2023. Thousands of patients with sickle cell disease...
Los Angeles, Calif. – Samara Rahman, 74, considers herself lucky. She gets to take walks on the beach, go swimming and ride her bike — all things that were taken from her when she was diagnosed with pancreatic cancer in November of 2022. Pancreatic cancer is the third leading cause of cancer-related deaths...
Los Angeles, Calif. – Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma. CAR T-cell therapy uses genetically engineered versions of a...
FAIRFAX, Va. — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City. The traditional treatment options of radiation or...
A long-term study by researchers at UCLA’s Jonsson Comprehensive Cancer Center found that the three most common treatments for localized prostate cancer had significant impacts on patients’ quality of life, a finding that could help guide doctors and patients in making treatment decisions. The four-year study, which followed 475 men...
Los Angeles, Calif. – Preeclampsia (PE) is a significant contributor to the increase in maternal morbidity and mortality worldwide, with particularly alarming numbers in the United States, where it affects about 2–8% of pregnancies, resulting in premature birth with associated morbidities for their infants as well. A new study by...
Los Angeles, Calif. – A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted...
Los Angeles, Calif. – Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have uncovered new details about the role of a protein called interferon regulatory factor (IRF1) in cancer progression and treatment response, offering new insight that can potentially help improve the effectiveness of cancer immunotherapy. The study, published in Cell Reports, reveals...
San Diego, Calif. – In a groundbreaking study published in Cancer Discovery, scientists at the University of California San Diego School of Medicine leveraged a machine learning algorithm to tackle one of the biggest challenges facing cancer researchers: predicting when cancer will resist chemotherapy. All cells, including cancer cells, rely...